Startup Hims has long-term plans for custom weight loss shots

Dig­i­tal health com­pa­ny Hims & Hers plans to of­fer cus­tom ver­sions of wild­ly pop­u­lar weight loss shots even af­ter sup­ply short­ages re­solve, ac­cord­ing to an in­vestor re­port this week.

Hims’ stock $HIMS shot up 30% on Mon­day when it said it was jump­ing in­to the GLP-1 weight loss mar­ket with com­pound­ed semaglu­tide, an al­ter­na­tive prod­uct with the same ac­tive in­gre­di­ent as No­vo Nordisk’s drugs Ozem­pic and We­govy, which have shown pow­er­ful weight loss ef­fects. Hims’ ver­sion, made by com­pound­ing phar­ma­cy BPI Labs, costs $199 a month — a frac­tion of We­govy’s $1,350 list price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.